Nasdaq:US$16.42 (-0.27) | HKEX:HK$26.55 (-0.10) | AIM:£2.67 (-0.01)
上一篇文章   |   下一篇文章
公告及新聞稿, 監管通知 | 2020-11-27

Notification of Dilution of Voting Rights

London: Friday, November 27, 2020:  Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med (“Shares”). Each American Depositary Share (“ADS”) represents five Shares.  As announced on November 17, 2020, Chi-Med issued a total of 16,666,670 Shares (equivalent to 3,333,334 ADSs) to Canada Pension Plan Investment Board.  Chi-Med was notified on November 26, 2020 that this issuance diluted CK Hutchison’s holding[1] to 45.69 per cent of the total number of voting rights of Chi-Med.  The date on which the notification threshold was crossed was November 26, 2020. [1] Held through CK Hutchison’s indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.


About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit:



Investor Enquiries

Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786

Media Enquiries

Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
Zhou Yi, Brunswick +852 9783 6894 (Mobile)

Nominated Advisor

Freddy Crossley / Atholl Tweedie,
Panmure Gordon (UK) Limited
+44 (20) 7886 2500


1 個附件
查看通告 (PDF)